NCT02808325View on ClinicalTrials.gov

Study on the Efficacy and Safety of Gelaspan

PHASE3CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Hypovolemia
Interventions
DRUG

Gelaspan 4%

Gelaspan 4% combined with Sterofundin ISO

DRUG

Gelofusine 4%

Gelofusine 4% combined with Sodium Chloride

Trial Locations (3)

195271

"Road Clinical Hospital of JSC Russian Railways", Saint Petersburg

197341

North-Western Federal Medical Research Center n.a. V.A. Almazov, Saint Petersburg

198255

City Clinical Oncology Dispensary, Saint Petersburg

All Listed Sponsors
lead

B. Braun Medical LLC

INDUSTRY

NCT02808325 - Study on the Efficacy and Safety of Gelaspan | Biotech Hunter | Biotech Hunter